GoAI
Get started
New Century Healthcare Holding Co. Limited logo

New Century Healthcare Holding Co. Limited

1518.HK

HKSEHealthcareMedical - Care Facilities

Open in GoAI

Latest quote

HK$0.248

+HK$0.008 · +3.33%

Aug 21, 4:08 PM HKT

1518.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

New Century Healthcare Holding Co. Limited functions as an investment enterprise, providing medical services specifically designed for women and children throughout the People's Republic of China. Its principal activities include specialized care in paediatrics, obstetrics, and gynaecology, complemented by hospital advisory services. Furthermore, the company offers digital healthcare solutions and operates on-site amenities like cafeterias and gift shops within its medical facilities. This entity was founded in 2002 and maintains its headquarters in Beijing, China.

Industry
Medical - Care Facilities
Sector
Healthcare
Headquarters
CN
CEO
Jason Zhou
Listed since
Jan 19, 2017
Employees
1,186

Market position

Day range

Current HK$0.248

52-week range

Current HK$0.248

Open
HK$0.24
Previous close
HK$0.24
Volume
50K
0.94× average
Average volume
53.34K
Average daily volume
Market cap
121.01M HKD
Beta
0.05
Market reference 1
50-day average
HK$0.3528
-29.71% below average
200-day average
HK$0.5506
-54.96% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
222.39M CNY
P/E (TTM)
-0.89×
P/B (TTM)
0.24×
P/S (TTM)
0.17×
EV / EBITDA
67.8×
Earnings yield
-40.26%
Free cash flow yield
2.89%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
29.31%
Operating margin
-11.83%
Net margin
-19.22%
Return on equity
-26.88%
Return on assets
-15.46%
Return on invested capital
-13.19%

Financial health

Debt / equity
0.39×
Current ratio
1.29×
Altman Z-score
-1.11
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends53%17%-20%-56%Gross margin, FY2021: 31.42%Gross margin, FY2022: 31.76%Gross margin, FY2023: 43.63%Gross margin, FY2024: 40.75%Gross margin, FY2025: 29.31%Operating margin, FY2021: -7.09%Operating margin, FY2022: -43.78%Operating margin, FY2023: 18.41%Operating margin, FY2024: 16.77%Operating margin, FY2025: -11.83%Net margin, FY2021: -16.04%Net margin, FY2022: -46.78%Net margin, FY2023: 9.02%Net margin, FY2024: 5.60%Net margin, FY2025: -19.22%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 31.42%. Gross margin FY2022 31.76%. Gross margin FY2023 43.63%. Gross margin FY2024 40.75%. Gross margin FY2025 29.31%. Operating margin FY2021 -7.09%. Operating margin FY2022 -43.78%. Operating margin FY2023 18.41%. Operating margin FY2024 16.77%. Operating margin FY2025 -11.83%. Net margin FY2021 -16.04%. Net margin FY2022 -46.78%. Net margin FY2023 9.02%. Net margin FY2024 5.60%. Net margin FY2025 -19.22%.

Income trends

Revenue

600.1M CNY-29.11%

Operating income

−71M CNY−212.97M CNY

Net income

−115.31M CNY−162.69M CNY
Income trends across reported periods1.06B CNY563.83M CNY71.51M CNY−420.81M CNYRevenue, FY2021: 632.57M CNYRevenue, FY2022: 636.46M CNYRevenue, FY2023: 933.07M CNYRevenue, FY2024: 846.5M CNYRevenue, FY2025: 600.1M CNYOperating income, FY2021: −44.85M CNYOperating income, FY2022: −278.65M CNYOperating income, FY2023: 171.81M CNYOperating income, FY2024: 141.97M CNYOperating income, FY2025: −71M CNYNet income, FY2021: −101.46M CNYNet income, FY2022: −297.73M CNYNet income, FY2023: 84.16M CNYNet income, FY2024: 47.38M CNYNet income, FY2025: −115.31M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 632.57M CNY. Revenue FY2022 636.46M CNY. Revenue FY2023 933.07M CNY. Revenue FY2024 846.5M CNY. Revenue FY2025 600.1M CNY. Operating income FY2021 −44.85M CNY. Operating income FY2022 −278.65M CNY. Operating income FY2023 171.81M CNY. Operating income FY2024 141.97M CNY. Operating income FY2025 −71M CNY. Net income FY2021 −101.46M CNY. Net income FY2022 −297.73M CNY. Net income FY2023 84.16M CNY. Net income FY2024 47.38M CNY. Net income FY2025 −115.31M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue600.1M CNY846.5M CNY933.07M CNY636.46M CNY632.57M CNY
Cost of goods sold424.22M CNY501.54M CNY525.99M CNY434.32M CNY433.83M CNY
Gross profit175.88M CNY344.96M CNY407.09M CNY202.14M CNY198.74M CNY
Research and development3.31M CNY4.08M CNY5.93M CNY7.7M CNY10.57M CNY
Selling, general, and administrative184.73M CNY192.73M CNY198.15M CNY194.11M CNY217.24M CNY
Operating expenses246.88M CNY202.99M CNY235.28M CNY480.79M CNY243.59M CNY
Interest income2.69M CNY4.9M CNY1.32M CNY2.07M CNY3.06M CNY
Interest expense6.52M CNY7.61M CNY8.06M CNY13.03M CNY14.3M CNY
Depreciation and amortization20.52M CNY27.95M CNY59.98M CNY70.25M CNY86.62M CNY
Operating income−71M CNY141.97M CNY171.81M CNY−278.65M CNY−44.85M CNY
Net income−115.31M CNY47.38M CNY84.16M CNY−297.73M CNY−101.46M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.11

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.2-0.07-0.35-0.62Q3 '22Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25Q2 '25Q1 '26
Q3 2022, reported Aug 31, 2022: actual -0.562, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 28, 2023: actual -0.151, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 31, 2023: actual 0.052, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 28, 2024: actual 0.144, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 27, 2024: actual 0.056, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 27, 2025: actual 0.049, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 22, 2025: actual -0.153, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 27, 2026: actual -0.111, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates621.92M515.94M409.96M303.99MQ3 '22MissQ1 '23MissQ3 '23MissQ1 '24MissQ3 '24No estimateQ1 '25No estimateQ2 '25No estimateQ1 '26No estimate
Q3 2022, reported Aug 31, 2022: actual 327.91M HKD, estimate 598M HKD, surprise -45.17%, Miss. Q1 2023, reported Mar 28, 2023: actual 405.86M HKD, estimate 598M HKD, surprise -32.13%, Miss. Q3 2023, reported Aug 31, 2023: actual 450.02M HKD, estimate 598M HKD, surprise -24.75%, Miss. Q1 2024, reported Mar 28, 2024: actual 572.15M HKD, estimate 598M HKD, surprise -4.32%, Miss. Q3 2024, reported Aug 27, 2024: actual 446.7M HKD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 27, 2025: actual 458.01M HKD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 22, 2025: actual 333.18M HKD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 27, 2026: actual 328.82M HKD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.0221

2025 complete year-55.8% since 2018

Corporate action history

Dividend

Ex-dividend May 29, 2025

HK$0.0221

Annual

Record Jun 2, 2025 · Payment Jul 2, 2025

Dividend

Ex-dividend May 29, 2024

HK$0.0378

Annual

Record May 31, 2024 · Payment Jul 2, 2024

Dividend

Ex-dividend Jun 4, 2018

HK$0.05

Annual

Record Jun 5, 2018 · Payment Jul 3, 2018

1518.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.4

-4.08%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.30

-3.94%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.8

-2.72%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.54

-4.82%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.14

-5.86%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.5

-1.86%

Continue in GoAI

Research 1518.HK

research.disclaimer